After overcoming a financial shortfall in 2024, Inventiva is cutting staff by 50% and ceasing its preclinical research and development efforts to try to make its money last long enough to get Phase III data for its metabolic dysfunction-associated steatohepatitis (MASH) candidate lanifibranor, expected during the second half of 2026.
Key Takeaways
- With current runway only into Q3 of this year, Inventiva announced a 50% staff cut to get it to the finish line for Phase III data in MASH.
Once viewed as potentially second in line to reach the market with a MASH drug, Inventiva has fallen off that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?